Primary pulmonary malignant hemangiopericytoma associated with coagulopathy. 1997

Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
Department of Surgery, Veterans General Hospital-Taipei, Taiwan, Republic of China.

A 34-year-old woman with a massive pulmonary malignant hemangiopericytoma and coagulopathy as a paraneoplastic syndrome is reported. Although coagulopathy may appear as a paraneoplastic syndrome and cause treatment to be more complicated and difficult, it can also be a useful marker to monitor the results of operation and tumor recurrence. This unusual case shows that primary pulmonary malignant hemangiopericytoma deserves aggressive surgical intervention with complete resection even under the circumstances of coagulation abnormality.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010257 Paraneoplastic Syndromes In patients with neoplastic diseases a wide variety of clinical pictures which are indirect and usually remote effects produced by tumor cell metabolites or other products. Paraneoplastic Syndrome,Syndrome, Paraneoplastic,Syndromes, Paraneoplastic
D011013 Pneumonectomy The excision of lung tissue including partial or total lung lobectomy. Bronchoscopic Lung Volume Reduction,Endoscopic Lung Volume Reduction,Lung Volume Reduction,Lung Volume Reduction Surgery,Partial Pneumonectomy,Partial Pneumonectomies,Pneumonectomies,Pneumonectomy, Partial,Reduction, Lung Volume,Volume Reduction, Lung
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D001780 Blood Coagulation Tests Laboratory tests for evaluating the individual's clotting mechanism. Coagulation Tests, Blood,Tests, Blood Coagulation,Blood Coagulation Test,Coagulation Test, Blood,Test, Blood Coagulation
D005260 Female Females
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses

Related Publications

Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
January 1998, Clinical imaging,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
September 2007, Clinical lung cancer,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
August 1977, The Journal of thoracic and cardiovascular surgery,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
February 1987, Cancer,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
December 1991, [Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
November 2019, Archivos de bronconeumologia,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
May 1979, Lijecnicki vjesnik,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
January 2008, Lung,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
March 1985, Annales de chirurgie,
Y C Wu, and L S Wang, and W Chen, and H J Fahn, and M H Huang, and J Whang-Peng
September 1985, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Copied contents to your clipboard!